Our latest COVID-19 information - full Autumn programme of webinars now in place

Common Technical Document Training Course

A comprehensive review of the regulations and technical requirements for chemistry, manufacturing and control (CMC) management of your application.

1-2 Dec 2020

& 2-3 Jun 2021 , 9-10 Jun 2021 , 29-30 Nov 2021 , 1-2 Dec 2021

Book now

Details

Course Overview

This interactive two-day course will provide you with a clear and comprehensive understanding of the regulatory and technical requirements for CMC management of your full and generic application in major markets of the EU and USA..

Furthermore, the course examines the requirements for global roll-out of the dossier to ROW regions including LATAM, ASEAN, MENA and CIS territories.

You will increase your ability to manage all aspects of development of the CMC applications after two days of intensive lectures, group work and discussion sessions, covering everything you need to know about compiling the chemistry and pharmacy section of your generic dossier.

Skills you will gain include:

  • Effective compilation of the Common Technical Document (CTD) and critical review of documentation
  • Quality by design (QbD), critical attributes and developing new product using the CQA pyramid model
  • Compiling and submitting Module 3 (CTD) of your registration dossier
  • Identifying the extent of content expected by EU and US regulators
  • Achieving the quickest turnaround of your submission
  • Managing the pharmaceutical and quality aspects of your developments and registration dossier in Europe and the US
  • Ensuring right-first-time development
  • Meeting the legal framework and guidelines for the CMC/quality part of the dossier and links to GMP

Who should attend

  • Senior analytical chemists
  • Formulation chemists
  • Technical services chemists
  • Registration staff (all levels)
  • Quality managers
  • Quality control directors
  • R&D project managers

Programme

What is the CTD?

  • The road map to Module 3 and understanding ICH
  • Assessing the impact of harmonisation – ICH guidelines

Preparing the drug substance section of the application – US and EU

  • Analysing the needs for the section
  • How to submit information – drug master files, certificates of suitability (CEP) and other methods
  • European submissions, CEP and active substance master file (ASMF) requirements
  • Detailed information requirements for the section
  • Q11 explained – EU and US expectations of failure mode and effects analysis (FMEA)
  • Development expectations and scale-up requirements
  • Specific examples of EU/US format and guidance

GMP for active substances

  • Examining GMP requirements and EU and US expectations, inspection timing and interactions and contractual obligations

Case study: Essential information from API suppliers

  • Identify and understand the essential data requirements from API suppliers for submission of generic applications

Examining the content of the sections concerning the drug product composition and development of the drug product

  • Defining the formulation
  • Identifying the data needs for the pharmaceutical development section, explaining QbD and FMEA requirements
  • Multiple examples of development report content – practical for table of contents and creation of QbD pyramid

Writing the section on manufacture of the drug product and process validation

  • Examining the content of the section: how much information to provide
  • Defining the difference between process development and validation and looking at validation expectations in today’s environment

Writing the sections on excipients and packaging components

  • Control of the excipients/packaging components
  • Examples of data expectations
  • Examining the maintenance of these sections

Writing the sections on control of the finished product and case study

  • Examining the content of the section
  • Control of the drug product
  • Examples of specifications for multiple product types
  • Examples for method summaries

Writing the stability section

  • Examining the content of the section
  • Evaluation of stability data and the impact on shelf life

The function and content of the Quality Overall Summary (QOS)

  • Overview of the current approaches
  • What is the Expert Report: practical involvement of the expert
  • QOS explained and compared with Expert Report
  • Detailed content of the QOS

Examining global roll-out of Module 3

Examining change control – practical tips

Practical exercise in generic development

  • Identifying ten-stage plan for developments

Presenter

Andrew Willis (More...)

Andrew Willis is an independent consultant providing expert advice and training on global regulatory solutions and pharmaceutical development. Previously, he worked for Catalent Pharma Solutions as VP Regulatory Affairs & Consulting Services, where he was head of a team of internal and external regulatory affairs consultants.

He qualified as a Chemist from the University of Glamorgan, after which he furthered his understanding of pharmaceutical development, working as a research chemist with Parke Davis. He had 10 years manufacturing and analytical experience prior to entering regulatory affairs as a Senior Executive Officer with responsibility for submission of European MAAs and project management of development programs. He has over 30 years’ pharmaceutical experience with extensive knowledge in the development and manufacture of sterile, solid oral, inhalation, topical and biotech pharmaceutical products. These experiences have allowed knowledge of many biotech products requirements with experiences of growth hormones and multiple cancer treatments, including development and clinical registration of the first genetically modified live bacterium for such treatment.
He has extensive experience of major European and US regulatory projects, in the clinical and marketing authorisation stages, and has significant experience in coordinating and managing meetings with European and US Health Authorities.

Book now

Book now

1-2 Dec 2020
Live webinar
1-2 Dec 2020
Live webinar
GBP 1,099.00
EUR 1,579.00
USD 1,787.00
Until 20 Oct*
Enrol now
to attend
Live webinar
2-3 Jun 2021
Live webinar
2-3 Jun 2021
Live webinar
GBP 1,099.00
EUR 1,579.00
USD 1,786.00
Until 21 Apr 21*
Enrol now
to attend
Live webinar
9-10 Jun 2021
Face-to-face, (venue not yet confirmed)
9-10 Jun 2021
Face-to-face
(venue not yet confirmed)
GBP 1,299.00
EUR 1,819.00
USD 2,026.00
Until 28 Apr 21*
Enrol now
to attend
Face-to-face
(venue not yet confirmed)
  • 2 days of classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy
29-30 Nov 2021
Face-to-face, (venue not yet confirmed)
29-30 Nov 2021
Face-to-face
(venue not yet confirmed)
GBP 1,299.00
EUR 1,819.00
USD 2,026.00
Until 18 Oct 21*
Enrol now
to attend
Face-to-face
(venue not yet confirmed)
  • 2 days of classroom-based training
  • Meet presenters and fellow attendees in person
  • Lunch and refreshments provided
  • Download documentation and certification of completion
  • Fair transfer and cancellation policy
1-2 Dec 2021
Live webinar
1-2 Dec 2021
Live webinar
GBP 1,099.00
EUR 1,579.00
USD 1,786.00
Until 20 Oct 21*
Enrol now
to attend
Live webinar

Learn more about our face-to-face and webinar training formats.

* Note the early booking discount cannot be combined with any other offers or promotional code

Customised in-house training

We can customise this course to meet the requirements of your organisation and deliver it at your location and/or online.

Contact us

You may also be interested in

Previous customers include...

  • Actavis UK Ltd, a subsidiary of Accord Healthcare Ltd
  • Actelion Pharmaceutical Ltd
  • argenx bvba
  • Bayer AG
  • Beaphar B.V.
  • Biovet JSC
  • DNDi
  • Elanco UK AH Limited
  • ELPEN Pharmaceutical Co. Inc.
  • Ferring Pharmaceuticals Inc
  • Furtado Consultancy Limited
  • GE Healthcare AS
  • GlaxoSmithKline Vaccines & Diagnostics s.r.l.
  • Guerbet
  • GW Pharmaceuticals
  • Liansa Pharma Consulting AB
  • M & A Pharmachem Ltd
  • Masters Speciality Pharma
  • Morningside Healthcare Ltd
  • MSD
  • Niacet b.v.
  • ObsEva SA
  • PhaRA
  • PHARA+
  • Pharmex Advanced Laboratories, S.L.
  • Recipharm AB
  • Recipharm Pharmaceutical Development AB
  • Research and Markets
  • Rottapharm Ltd
  • Teva UK Ltd

Excellent presentation by a first-class speaker who has a wealth of knowledge. I particularly liked the interactive exercises.

Wil Pantin, New Product Introduction Manager, M & A Pharmachem Ltd, Dec 19

Great speaker, capable of transmitting his knowledge in an enjoyable and interactive way.

Rocio Arias, Regulatory Affairs Technician , Pharmex Advanced Laboratories, S.L., Dec 19

It was one of the best workshops I have attended: content was according to expectations, all questions were answered, presenter was passionate and kept the energy high during the presentations.

Iris Vanwelkenhuysen, CMC Dossier Leader, Galapagos, Dec 19

The speaker was not only very professional, but also kept the mood light and fun. I enjoyed his way of putting things into perspective and making me think in a whole other way from what I am used to. The exercises ... helped with better understanding the material. Overall, a really good course and a great speaker giving both theoretical and practical tools to understand the CTD and importance of the Module 3.

Joanna Sadiq, Regulatory Manager, LINK Medical ApS, Jul 19

Excellent!

Vilma Smith, Manager, Regulatory CMC, Celgene Europe Ltd, Jul 19

Good speaker, updated information and good discussions. The group assignments were terrific for learning and understanding.

Hilde Reiersen, Research Scientist, GE Healthcare AS, Jul 19

Excellent speaker! Good interaction! Wonderful course.

Marjana Grønvall, Regulatory affairs professional, ALK-Abelló A/S, Dec 18

Superbly knowledgable speaker and great training style - content was very helpful

Andrew Germain, Associate Director, CMC Regulatory Affairs, GW Pharmaceuticals, Dec 18

Very clean. Very clear speaker. Presentation and content are well adapted.

Sonia Bchir Kassassi , Regulatory Affairs CMC Expert, GUERBET, Jul 18

Very lively presentation, interactivity, exercises to keep the interest.

Natacha Gonzalez, CMC Dossier & Compliance Specialist, Ares Trading S.A., Jul 18

I really enjoyed the presentation, which I found really interesting.

Maria Biri, CMC Dossier Development & Coordination Supervisor, ELPEN Pharmaceutical Co. Inc., Dec 17

Experienced speaker

Julie de Smet, Regulatory Affairs Consultant, PharmaVize NV, Dec 17

Very interactive course. Very interesting.

Fanny Valleix, Head Clinical Research, ImmuPharma , Dec 17

The content of presentation was very good and covered the major sections of CTD. The speaker was very keen to answer all questions.

Ewelina Dulko, Senior Formulation Scientist, Wockhardt, Dec 17

Very professional

Evdoky El Harran, Regulatory Affairs Associate, Pierre Fabre Medicaments, Jul 17